Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Withalongolide B is a naturally occurring withanolide, a type of C28 steroidal lactone, isolated from the plant *Physalis longifolia*. It is characterized as a potent anti-proliferative and cytotoxic agent with potential therapeutic applications in oncology. Research conducted primarily at the University of Kansas has identified withalongolide B as a lead compound for the development of novel chemotherapeutic agents, demonstrating significant activity against various cancer cell lines, including head and neck squamous cell carcinoma and melanoma. Its mechanism of action is associated with the inhibition of the Heat shock protein 90 (Hsp90) chaperone machinery, which leads to the degradation of oncogenic client proteins and the subsequent induction of apoptosis in cancer cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on withalongolide B.